Handok pharmaceuticals got approval of Phase 1 clinical trial for their first self-developed anti-inflammatory medication for autoimmune disease

Published: 2014-03-11 15:38:34

Updated: 2014-03-11 15:38:34

Handok pharmaceuticals (Chairman Kim, Young-Jin) got approval of Phase 1 clinical trial for their first self-developed anti-inflammatory medication for autoimmune disease 'HL2351', from Minister of Food and Drug Safety. This is Handok's first approved biopharmaceuticals developed through open Innovation strategy starting from 2006.

Handok's first biopharmaceuticals 'HL2351 (IL1Ra-hyFc)' aims t...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.